KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreTim Lowery serves as interim CEO for KBI Biopharma and Selexis. Tim joined JSR in 1996..
Abdelaziz brings more than two decades of global expertise in biotech, pharmaceutical, and CDMO industries.
Alberto joined Selexis with nearly 30 years of experience leading the...
Roland joined Selexis from Polpharma Biologics where he was head of business development, CDMO Europe.
Myriam joined Selexis in 2012 as project leader, managing and coordinating...
Ghislaine joined Selexis in July 2015 as Genomic Director responsible for...
David is director of cell line services. He is responsible for...
Séverine joined Selexis in December 2015 to lead the Cell Line...
Alexandre is Director of Molecular Biology for Selexis. Alexandre joined Selexis...
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Latest News
KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer
Read MoreSelexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders
Read MoreCopyright© 2023 Selexis SA. All Rights Reserved.